Evidence mapPaperPMID 42039261Full record

ArticleBiochemistry and biophysics reports2026

Oroxylin A ameliorates hepatic steatosis and non-alcoholic fatty liver disease through the regulation of CPT1A m

Yihong Ji, Han Gu, Mingyue Wang, Yuanshu Miao, Chunfeng Gao, Jinlin Zhang, Lin Luo

Abstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yihong JiDepartment of Pharmacy, Affiliated Tumor Hospital of Nantong University & Nantong Tumor Hospital, Nantong, Jiangsu, 226001, China.
Han GuSchool of Pharmacy, Nantong University, Nantong, Jiangsu, 226019, China.
Mingyue WangSchool of Pharmacy, Nantong University, Nantong, Jiangsu, 226019, China.
Yuanshu MiaoNursing Department, Affiliated Tumor Hospital of Nantong University & Nantong Tumor Hospital, Nantong, Jiangsu, 226001, China.
Chunfeng GaoNursing Department, Affiliated Tumor Hospital of Nantong University & Nantong Tumor Hospital, Nantong, Jiangsu, 226001, China.
Jinlin ZhangDepartment of Pharmacy, Affiliated Tumor Hospital of Nantong University & Nantong Tumor Hospital, Nantong, Jiangsu, 226001, China.
Lin LuoSchool of Pharmacy, Nantong University, Nantong, Jiangsu, 226019, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a chronic condition that is frequently observed worldwide and has become a threat to global public health. Excess accumulation of hepatic lipids contributes to NAFLD. Oroxylin A has attracted widespread attention because of its antioxidant and immunomodulatory activities. Nonetheless, its role in hepatic lipid metabolism remains unclear. In this work, in hepatocytes exposed to palmitic acid (PA), oroxylin A significantly reduced lipid accumulation by inhibiting lipogenesis. Mechanistic studies revealed that oroxylin A can regulate m

Indexed as

CPT1ALipogenesism6A demethylationNon-alcoholic fatty liver diseaseOroxylin A

Identifiers

PMID42039261
PMCPMC13103590

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.